Sarcopenia—A New Frontier in the Management Care of Patients With Borderline Resectable Pancreatic Cancer

Griffin, Oonagh; Conlon, Kevin C.

doi:10.1001/jamasurg.2018.1006

Cited by 6 publications

(1 citation statement)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anorexia and early satiety are induced by tumour-derived cytokines and are aggravated by pancreatic exocrine insufficiency and increased inflammation, leading to reduced nutritional intake, malabsorption, and increased resting energy expenditure [2]. Developments in body composition assessment methodologies [3,4] have highlighted the prognostic importance of sarcopenic obesity in advanced pancreatic cancer [5] and other solid tumours [6] supporting the argument that formal body composition assessment should be routine in clinical practice [7]. Griffin Pancreatic cancer surgery carries a significant risk of post-operative morbidity despite centralization to high volume centres and the refinement of surgical technique.…”

Section: Introductionmentioning

confidence: 99%

Measurement of Body Composition in Pancreatic Cancer: A Systematic Review, Meta-Analysis, and Recommendations for Future Study Design

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background/Objectives: Sarcopenia in pancreatic cancer may increase the risk of chemotherapy-related toxicity and post-operative morbidity. This systematic review and meta-analysis aimed to quantify the prevalence of sarcopenia in early stage pancreatic cancer. Methods: Relevant studies were identified using Ovid Medline and Elsevier Embase. Pooled estimates of prevalence rates (percentages) and corresponding 95% confidence interval (CI) were computed using a random-effects model to allow for heterogeneity between studies. Results: The majority of the thirty-three studies (n=5593 patients) included in this meta-analysis utilised computed tomography (CT)-derived measures for body composition assessment in patients undergoing pancreatic resection. Reported prevalence of sarcopenia varied between 14 and 74 %, and the pooled prevalence was 39% (95% CI 38- 40%) Heterogeneity was considerable however (I² 93%) and did not improve significantly when controlling for assessment method, and use of pre-defined cut-offs for sarcopenia, limiting potential to evaluate the true impact of sarcopenia. Conclusion: The ready availability of sequential CT offers a valuable opportunity for body composition assessment, but the quality of assessment and interpretation must improve before the impact of body composition on treatment-related outcomes and survival can be assessed. We suggest recommendations for the assessment of body composition for the design of future studies.

show abstract